1. Details of the 10 patients in the open-label trial PatientSymptomsResponseOutcome 1Acute confusional state and psychosis No signs or symptoms Relapse of nephritis at 22 m; rituximab reapplied but failed 2Acute confusional state No signs or symptoms Relapse of autoimmune hemolytic anemia at 18 m; rituximab reapplied and patient improved 3Acute confusional state and seizures No signs or symptoms Relapse of NPSLE at 23 m; IV cyclophosphamide Tanaka Y et al. Arthritis Rheum 2005; 52(9 Suppl):Poster 431. Rituximab for refractory neuropsychiatric SLE [Rheumawire > News; Nov 14, 2005]

2. Details of the 10 patients in the open-label trial PatientSymptomsResponseOutcome 4Severe headacheReduction of headache Remission maintained for 24 m 5Demyelinating syndrome Reduction of paresthesia Relapse of NPSLE at 7 m; IV cyclophosphamid e 6Mood disorderImprovement of depressive state Remission for 7 m Tanaka Y et al. Arthritis Rheum 2005; 52(9 Suppl):Poster 431. Rituximab for refractory neuropsychiatric SLE [Rheumawire > News; Nov 14, 2005]

3. Details of the 10 patients in the open-label trial PatientSymptomsResponseOutcome 7Myelopathy, mood disorder, anxiety disorder Reduction of paresthesia, improvement of depressive state Remission for 9 m 8Psychosis, cognitive dysfunction Improvement of psychosis Remission for 6 m 9Acute confusional state, psychosis No signs or symptoms Remission for 6 m 10Acute confusional state, psychosis No signs or symptoms Remission for 24 m Tanaka Y et al. Arthritis Rheum 2005; 52(9 Suppl):Poster 431. Rituximab for refractory neuropsychiatric SLE [Rheumawire > News; Nov 14, 2005]